This prospective randomized double-blind study evaluates the efficacy of erector spinae plane (ESP) blocks on postoperative pain in patients undergoing cervical or lumbar posterior spinal fusion. Patients will receive either 0.5% bupivacaine plus liposomal bupivacaine or 0.5% plain bupivacaine. Outcomes include opioid consumption over 72 hours, pain scores, length of stay, and time to ambulation.

Start Date01 Oct 2027

Sponsor / Collaborator

Duke University

NCT07097493

/ Not yet recruitingPhase 4IIT

Liposomal Bupivacaine vs Perineural Adjuvants in Adductor Canal and iPACK Blocks in Patients Undergoing Primary Total Knee Arthroplasty

The purpose of this research study is to compare two different combinations of anesthetic medications to see which works the best in providing the longest lasting pain relief for total knee arthroplasty surgery. The drugs being used are liposomal bupivacaine compared to a combination of bupivacaine, clonidine, epinephrine, buprenorphine, and dexamethasone. Pain scores will be collected at different intervals during study participation.

Start Date01 Feb 2027

Sponsor / Collaborator

Wake Forest School of Medicine

ChiCTR2600125462

/ SuspendedNot ApplicableIIT

Effects of bupivacaine liposome versus ropivacaine hydrochloride on postoperative pain and recovery quality in patients undergoing robotic-assisted radical prostate cancer resection

Start Date01 Dec 2026

Sponsor / Collaborator

Zhejiang Lishui People's Hospital

100 Clinical Results associated with Bupivacaine liposome

100 Translational Medicine associated with Bupivacaine liposome

100 Patents (Medical) associated with Bupivacaine liposome

4,204

Literatures (Medical) associated with Bupivacaine liposome

31 Dec 2026·ANNALS OF MEDICINE

Liposomal bupivacaine versus ropivacaine for surgical site infiltration in lumbar fusion: a prospective randomized controlled trial

Article

Author: Li, Min ; Zhai, Wenwen ; Yue, Feng ; Lyu, Yanhan ; Qi, Qiang

INTRODUCTION:

Effective postoperative pain control after lumbar spine surgery remains challenging, and excessive opioid use is associated with adverse outcomes. Evidence comparing liposomal bupivacaine (LB) with conventional long-acting local anesthetics in spine surgery is limited.

PATIENTS AND METHODS:

In this single-center, prospective, randomized, patient- and outcome assessor-blinded trial, adult undergoing one- or two-level posterior lumbar decompression and fusion were assigned (1:1) to surgical site infiltration with either LB (266 mg) plus 25 mg plain bupivacaine (LB group) or ropivacaine (R group). The primary outcome was 72 h cumulative opioid consumption (morphine milligram equivalents, MME). Secondary outcomes included time-profile opioid consumption, pain scores, rescue analgesia, safety, and functional recovery.

RESULTS:

A total of 202 patients were included in the modified intention-to-treat analysis. Cumulative MME within 72 h was significantly lower in the LB group compared with the R group [43.0 (37.0, 58.0) mg vs. 58.0 (46.0, 73.0) mg], corresponding to a 22% relative reduction (GMR 0.78, 95% CI 0.71-0.85; p < 0.001). The reduction was most pronounced during 8-24 h and 24-48 h postoperatively. Overall pain scores at rest and with movement, as well as 72-h pain AUC, were lower in the LB group. No significant between-group differences were observed in rescue analgesia, adverse events and functional recovery.

CONCLUSION:

In patients undergoing one- or two-level posterior lumbar decompression and fusion, surgical site infiltration with an LB-based combined regimen, compared with ropivacaine monotherapy, reduced 72-h opioid consumption and cumulative postoperative pain burden without an observed increase in adverse events or impairment of early functional recovery.

31 Dec 2026·ANNALS OF MEDICINE

Comparison of liposomal bupivacaine and bupivacaine hydrochloride intercostal nerve blocks for postoperative analgesia after thoracic surgery: a multicenter, randomized, three arms trial protocol

Article

Author: Wang, Lihua ; Huang, Junyi ; Lv, Xin ; Liu, Hang ; Yang, Yiming ; Xin, Yuxuan ; Wei, Shiyou ; Chang, Rui ; Song, Jiong

INTRODUCTION:

Whether intercostal nerve block can fully realize the prolonged analgesic potential of liposomal bupivacaine remains uncertain. This study aims to evaluate whether liposomal bupivacaine administered via intercostal nerve block confers a long-acting analgesic advantage over bupivacaine hydrochloride and no block within the postoperative 25-72 h window.

PATIENTS AND METHODS:

This is a multicenter, randomized, parallel, three-arm controlled trial planning to enroll 210 patients undergoing elective unilateral video-assisted thoracoscopic surgery. Using center-stratified block randomization (1:1:1), patients will be allocated at the end of surgery to receive an intercostal nerve block with liposomal bupivacaine, bupivacaine hydrochloride, or no block. All patients will follow a standardized general anesthesia and multimodal analgesia protocol. The primary outcome is the area under the curve for pain scores during the postoperative 25-72 h. Other outcomes include pain verbal response scale at predefined time points, cumulative postoperative morphine milligram equivalent consumption, sensory block recovery time, 15-item quality of recovery scale, postoperative nausea and vomiting, postoperative pulmonary complications, length of hospital stay.

DISCUSSION:

This study prospectively evaluates the central question of whether liposomal bupivacaine confers a clinically meaningful long-acting analgesic advantage when used in the context of nerve block. By focusing on the area under the curve of pain scores and incorporating patient-centered outcomes such as opioid consumption and quality of recovery, the study aims to generate high-quality, translatable evidence to define the role of liposomal bupivacaine in thoracic surgery.

CLINICAL TRIAL REGISTRATION:

Clinicaltrials.org, NCT07134660.

31 Dec 2026·ANNALS OF MEDICINE

Thoracic paravertebral block with different doses of liposomal bupivacaine versus ropivacaine for postoperative analgesia in single-port thoracoscopic lung surgery: a randomized clinical trial

Article

Author: Wang, Yanping ; Ren, Liyuan ; Li, Yanshuang ; Nan, Zhenhua

OBJECTIVE:

To evaluate the analgesic efficacy of thoracic paravertebral block (TPVB) with different doses of liposomal bupivacaine (LB) or ropivacaine in patients undergoing single-port thoracoscopic lung surgery.

METHODS:

A total of 105 patients scheduled for video-assisted single-port thoracoscopic lung surgery were randomized in a 1:1:1 ratio into three groups: low-dose LB group (group LL), high-dose LB group (group HL), or ropivacaine group (group R). All received ultrasound-guided TPVB at the T5/6 level preoperatively. The primary outcome was the area under the curve (AUC) of NRS of pain at activity (AUC-aNRS) from 1 to 72 h postoperatively. Secondary outcomes included the AUC of NRS of pain at rest (AUC-rNRS) from 1 to 72 h postoperatively, NRS of pain at rest and at activity at 1, 6, 24, 48, and 72 h postoperatively, and the cumulative opioid consumption at 24, 48, and 72 h postoperatively. Additionally, postoperative recovery and adverse events were assessed.

RESULTS:

AUC-aNRS differed significantly among groups (p = 0.0092), with high-dose LB lower than low-dose LB (p = 0.0071), but not versus ropivacaine. No significant difference was found in AUC-rNRS (p > 0.05). The group-by-time interactions for NRS of pain at rest and at activity were not significant (p > 0.05). Cumulative opioid consumption at 24, 48, and 72 h was lower in group HL versus group LL (all p < 0.017), but not versus ropivacaine. Postoperative recovery and adverse events showed no differences (p > 0.05).

CONCLUSION:

LB combined with TPVB is not superior to ropivacaine for postoperative analgesia in single-port thoracoscopic lung resection.

News (Medical) associated with Bupivacaine liposome

19 Oct 2026

·www.biospace.com

TLC590 Achieves Statistically Significant Reductions in Pain and Opioid Use Versus Both Placebo and Liposomal Bupivacaine in Pivotal Phase 3 Trial

Met Primary Endpoint: Significant pain reduction through 72 hours vs. placebo. Significantly Reduced Opioid Use: Outperformed both placebo and liposomal bupivacaine head-to-head in pain reduction and opioid consumption. Prolonged Efficacy: A single dose sustained significant pain relief versus both comparators through 7 days. TAIPEI, Taiwan and SOUTH SAN FRANCISCO, Calif., Oct. 19, 2026 (GLOBE NEWSWIRE) -- TLC BioSciences Corp. (TPEx: TLC-KY; ticker: 7924; “TLC”) today announced positive topline results from its pivotal Phase 3 trial of TLC590, an investigational extended-release formulation of ropivacaine, for the management of postsurgical pain following bunionectomy. The trial met its primary endpoint, with TLC590 significantly reducing pain intensity through 72 hours after surgery compared with placebo (p=0.0024); rescue opioid consumption was also significantly lower. In a head-to-head comparison with liposomal bupivacaine, an approved long-acting local anesthetic, TLC590 also demonstrated statistically significant superiority in both pain intensity and rescue opioid consumption. The analgesic benefit of TLC590 over both comparators was maintained through 168 hours. These results support the potential of TLC590 as a single-dose, non-opioid option for durable postsurgical pain relief with reduced opioid use. Compared with placebo, TLC590 significantly reduced cumulative pain intensity with movement through 72 hours after surgery (NRS-M AUC0–72h; p=0.0024), meeting the primary endpoint, and significantly reduced total rescue opioid consumption over the same period (p=0.0109). In the head-to-head comparison with liposomal bupivacaine, TLC590 demonstrated statistically significant superiority in cumulative pain intensity through 72 hours (NRS-M AUC0–72h; p=0.0202), and significantly reduced rescue opioid consumption (p=0.0177). Over the extended 168-hour assessment period, TLC590 maintained a statistically significant reduction in cumulative pain intensity versus both placebo (NRS-M AUC0–168h; p=0.0168) and liposomal bupivacaine (p=0.0226). “This Phase 3 success is a transformative milestone for TLC and a potential paradigm shift in postsurgical care,” said George Yeh, Chief Executive Officer of TLC BioSciences. “Addressing the opioid crisis requires treatments that deliver robust pain relief while actively reducing opioid dependence. By demonstrating a clear clinical advantage over the current commercial standard of care, TLC590 has proven it can do exactly that. With this highly de-risked clinical profile, our team is fully focused on advancing our NDA and bringing this critical non-opioid option to patients and providers as efficiently as possible.” “There remains a significant need for non-opioid options that provide durable analgesia beyond the first few days after surgery,” said David Leiman, MD, MBA, President, Acute and Chronic Pain, at Evolution Research Group, and an investigator in the TLC590 Phase 3 trial. “I am highly encouraged by these results. Demonstrating statistically significant superiority over both placebo and liposomal bupivacaine, with a treatment effect sustained through 168 hours from a single dose, is a meaningful achievement in the well-established bunionectomy model. These data suggest that TLC590 has the potential to provide sustained pain control through the critical first postoperative week while reducing reliance on opioids.” Next Steps: NDA Preparation and Commercialization These topline results, particularly the superiority demonstrated over liposomal bupivacaine, provide a strong clinical foundation and clear differentiation for TLC590 in the postsurgical pain market. TLC will complete the full data analysis and clinical study report, advance preparations for a New Drug Application (NDA) submission to the US FDA, and prepare for the commercialization of TLC590, with the goal of making it available to postsurgical patients as quickly as possible. About the TLC590 Phase 3 Trial This randomized, double-blind, placebo- and active-controlled Phase 3 trial evaluated the efficacy and safety of TLC590 for postsurgical pain management in 304 patients undergoing bunionectomy in the United States. Patients were assigned 1:1:1 to receive TLC590 (n=100), liposomal bupivacaine (n=102), or placebo (n=102). The primary efficacy endpoint was the area under the curve of numeric rating scale pain intensity scores with movement through 72 hours after surgery (NRS-M AUC0–72h) for TLC590 versus placebo. Secondary efficacy endpoints included total rescue opioid consumption through 72 hours for TLC590 versus placebo, and comparisons of TLC590 with liposomal bupivacaine on both measures. A key efficacy endpoint evaluated NRS-M AUC through 168 hours (AUC0–168h) for TLC590 versus both control groups. TLC590 was generally well tolerated, with a safety pro to placebo and liposomal bupivacaine. There were no drug-related serious adverse events or discontinuations due to drug-related adverse events in TLC590-treated patients. Dawn Chi / Corporate Communications / dawn@tlcbio.com

Phase 3Clinical Result

17 Oct 2026

·healthcare-digital.com

Stryker, Viatris, Flo, Teva, J&J: This Week in Healthcare

Spencer Stiles (left) will replace current CEO Kevin Lobo (right) from 1 January 2027. Credit: Stryker This week's top stories include Stryker's CEO change, Viatris' pain management deal, J&J's Q3 earnings and Flo and Google's femtech partnership 1. Stryker CEO Change: Spencer Stiles to Replace Kevin Lobo After 14 years at Stryker 's helm, during which time company revenue tripled, Kevin Lobo is stepping down as CEO and will begin his transition to the Executive Chair position. Spencer Stiles, who has spent nearly three decades at the US medtech firm, will replace Kevin. Most recently, Spencer was the company's COO, a position he only assumed in January 2026. Stryker's CEO succession process is already underway but will formally be completed on 1 January 2027. On LinkedIn following the announcement, Spencer writes: “It is a tremendous privilege to lead a company with such a rich history, exceptional culture, and purpose-driven mission. I am grateful to Kevin and our Board for their trust and confidence, and I am energised by the opportunity and responsibility to build on the strong foundation that has made Stryker a global leader in medical technology. “Throughout my career at Stryker, I have seen firsthand what sets our company apart: our talented people, our unwavering commitment to customers and our relentless focus on innovation.” 2. Viatris to Acquire Pacira in US$1.65bn Pain Management Deal Central to Viatris’ decision to acquire Pacira is the opportunity to strengthen its position in non-opioid pain management. Credit: Viatris In the latest pharmaceutical industry deal, Viatris has announced plans to acquire Pacira BioSciences , a specialist in innovative non-opioid pain therapies. The deal, thought to be worth around US$1.65bn, adds Pacira’s two patented medicines, acute post-surgical pain therapy Exparel and osteoarthritis knee pain treatment Zilretta, to Viatris’ portfolio. Pacira generated approximately US$746m in total revenue during the last twelve months ended 30 June 2026. Viatris CEO Scott Smith says the acquisition marks a further step in the company’s strategy to strengthen its innovative medicines portfolio and drive sustainable growth. On LinkedIn, following the announcement, Scott writes that the deal “advances the strategy we laid out earlier this year – to drive our base business, fuel our innovative portfolio and modernise for sustainable growth. “Pacira brings established medicines, a promising pipeline and important capabilities that complement our existing portfolio and strengthen our position in non-opioid pain management, an area of significant unmet need. “Just as importantly, this is about where we go from here. We see an opportunity to build on these medicines and capabilities to support the continued growth of our innovative medicines portfolio.” 3. J&J Q3 Earnings: The US$100bn Revenue Goal Remains in Reach Johnson & Johnson has not tried to hide its 2026 revenue goal. The US$100bn figure – the highest in its 140-year history – has been a target referenced in its earnings reports throughout the year. On 13 October 2026, the pharmaceutical giant published its Q3 earnings report, beating earnings estimates and recording total quarterly sales of US$25.4bn. In doing so, Johnson & Johnson has also raised its full-year guidance to US$101.2bn. “Johnson & Johnson’s strong third-quarter performance and increased sequential growth reflect the accelerating momentum of our focused portfolio,” explains CEO Joaquin Duato . “This progress, together with strategic investments in high-growth areas, gives us clearer line of sight to double-digit growth by the end of the decade,” he continues. Central to Johnson & Johnson’s continued success in 2026 is, according to Chief Financial Officer Joseph Wolk, the company’s “diversified portfolio.” J&J's portfolio now includes 29 products and platforms generating at least US$1bn in annual sales, spanning its Innovative Medicine and MedTech divisions. 4. Google & Flo Health Launch Wearable Femtech Partnership The Flo app allows users to track, record and view personalised guidance at each stage of their menstrual cycle. Credit: Flo Google has announced its latest strategic partnership, which will see the global technology giant collaborate with leading women’s health platform Flo Health to integrate the Flo app into Google’s wearable technology. With more than 80 million monthly users, the Flo app offers in-depth menstrual cycle tracking enhanced by AI and data-backed predictions. From early 2027, consenting users will have the ability to connect Flo with Google Fitbit, the company’s wearable health platform. “By teaming up with Flo, together with our personalised coaching, research expertise and 24/7 tracking, we can help women understand their health in entirely new ways,” says Rishi Chandra, Vice President and General Manager of Google Health. The multi-year partnership accompanies Google’s strategic investment in Flo Health. The companies have outlined plans for future collaborative research into women’s healthcare, aiming to produce new insights into hormonal symptoms and chronic conditions. 5. Teva Wins FDA Approval For Schizophrenia Innovation As World Mental Health Month draws global support for people with mental health conditions, healthcare providers are focusing on patient-centric drug innovation to provide a wider range of comfortable, accessible treatment options. The FDA approval of Weltruza, produced by leading generic pharmaceutical provider Teva, signifies a milestone within schizophrenia treatment. Teva describes Weltruza as the first once-monthly subcutaneous olanzapine formulation for adults with schizophrenia: combining the antipsychotic with long-acting injectable technology, it offers an alternative to daily oral medicines, which patients can face difficulty adhering to. “I’m incredibly proud of our R&D team and everyone across Teva who helped make this possible,” writes Eric A. Hughes, CMO and Head of R&D at Teva, on LinkedIn. “I’m especially grateful to the patients who participated in our clinical trials and the investigators who partnered with us along the way.” For Teva, Weltruza’s impending rollout represents a significant strategic achievement as the pharmaceutical company pivots towards developing its pipeline of innovative medicines. Company portals Flo Health Google Johnson & Johnson Pacira BioSciences Stryker Teva Pharmaceutical Viatris Executives Eric A. Hughes, MD, PhD Member Board of Directors Joaquin Duato Chairman of the Board and Chief Executive Officer Kevin Lobo Chair & CEO Rishi Chandra VP/GM for Health and Home Scott A. Smith Chief Executive Officer

Drug ApprovalExecutive ChangeAcquisition

12 Oct 2026

·www.pharmaceutical-technology.com

Viatris makes foray into non-opioid pain space on $1.65bn Pacira buyout

Viatris will acquire the rights to Exparel and Zilretta if this acquisition goes ahead. Credit: Dragana Gordic / Shutterstock.com. California-based healthcare company Viatris has inked a billion-dollar deal to acquire Pacira BioSciences and its non-opioid pain management therapies – allowing the company to enter a market attracting growing attention amid the ongoing effects from the opioid crisis in the US. Through this deal, Viatris will pay $36.50 in cash per share for Pacira’s remaining stock, bringing the buyout’s total value to $1.65bn. By taking Pacira under its wing, the healthcare giant will add two pain management drugs to its portfolio of generic and innovator medicines. The first of the drugs at the core of this deal is Exparel (bupivacaine liposome injectable suspension), which is approved in the US and Europe for pain management after surgery. The drug offers an extended-release form of local anaesthetic bupivacaine, which is designed to block the activity of sodium channels involved in the transmission of pain impulses. It is administered via an injection around the edges of a surgical wound, or close to the nerve that supplies an operation site. The second is Zilretta, which is currently the only pain management therapy specifically approved for knee osteoarthritis in the US. Zilretta acts by reducing joint inflammation linked to pain through its mechanism as an extended-release corticosteroid. If the transaction goes through as planned, Viatris will secure the rights to drugs on an upward revenue trajectory, with Exparel and Zilretta posting year-on-year growth of 3% and 4%, respectively, between Q2 2025 and Q2 2026. Currently, analysts at GlobalData, parent company of Pharmaceutical Technology, forecast that Exparel will approach blockbuster status in 2032, while Zilretta’s sales will peak at just over $150m in 2031. Viatris makes its Pacira takeover bid as several biotech and pharma companies take a growing interest in debuting non-opioid-based pain management medicines. This comes as some experts sound the alarm around dependency concerns surrounding long-term use of opioid-based therapies, with the US previously declaring the opioid epidemic a “national emergency” back in 2017. With Viatris set to enter the burgeoning non-opioid pain management market, it will have to compete with other players in the space such as Vertex Pharmaceuticals, which recently commercialised its selective sodium channel blocker, Journavx (suzetrigine), in moderate-to-severe acute pain – including post-operative. According to a recent report from GlobalData, 98% of pain medications currently on the market are generics, and neuropathic pain is the largest segment within the pain sector. However, pain is expected to be the largest growth driver within the disease area in the near future. The content above comes from the network. if any infringement, please contact us to modify.

Drug ApprovalAcquisition

100 Deals associated with Bupivacaine liposome

External Link

KEGG	Wiki	ATC	Drug Bank
D07552	Bupivacaine liposome	N01BB01	DB00297

R&D Status

Approved

10 top approved records.

to view more data

Indication	Country/Location	Organization	Date
Pain, Postoperative	United States	Pacira Biosciences, Inc.	28 Oct 2011

Developing

10 top R&D records.

to view more data

Indication	Highest Phase	Country/Location	Organization	Date
Back Pain	Phase 3	United States	Pacira Biosciences, Inc.	30 Apr 2024
Osteoarthritis, Knee	Phase 3	United States	Pacira Biosciences, Inc.	18 Jan 2022
Pain	Phase 3	United States	Pacira Biosciences, Inc.	22 Oct 2021
Analgesia	Phase 3	United States	Pacira Biosciences, Inc.	14 Apr 2021
Leg Injuries	Phase 3	United States	Pacira Biosciences, Inc.	20 Oct 2020
Ankylosis	Phase 3	-	Pacira Biosciences, Inc.	15 Jun 2020
Metatarsus Varus	Phase 3	-	Pacira Biosciences, Inc.	15 Jun 2020
Female Genital Neoplasms	Phase 3	United States	Pacira Biosciences, Inc.	31 Aug 2016
Brachial Plexus Neuritis	Phase 3	United States	Pacira Biosciences, Inc.	09 May 2016
Brachial Plexus Neuritis	Phase 3	Belgium	Pacira Biosciences, Inc.	09 May 2016

Clinical Result

Indication

Phase

Evaluation

View All Results

Study	Phase	Population	Analyzed Enrollment	Group	Results	Evaluation	Publication Date


NCT05900427 (CTgov)	Phase 4	Pain, Postoperative	78	Liposomal bupivacaine (Liposomal Bupivacaine Group)	gcemsidkoo: Odds Ratio (OR) = 1.9737 (95% CI, 0.6735 - 5.7843), P-Value = 0.2121 View more	-	06 Aug 2026
				Bupivacaine (Plain Bupivacaine Group)
NCT06547255 (CTgov)	Phase 4	Pain, Postoperative	100	Bupivacaine liposome injectable suspension	pbizelinnq(attmgckfop) = mvyxjcpwck gsviatqbwv (gwqcvljysy, 1.9) View more	-	28 Jul 2026
NCT05374499 (CTgov)	Phase 4	Pain, Postoperative	85	Liposomal bupivacaine (Liposomal Bupivacaine)	elwdivoqnl(wokimrajyr) = mehwqanvwv bpsdzjtjtn (jpvmvfeekz, ojimmrfhrv - etfinwczax) View more	-	04 Jun 2026
				epinephrine+bupivacaine (0.5% Bupivacaine With 1:200,000 Epinephrine)	elwdivoqnl(wokimrajyr) = yievclntnx bpsdzjtjtn (jpvmvfeekz, msulwerclv - eojqqpbplg) View more
NCT05992896 (CTgov)	Phase 4	Peripheral Arterial Disease	3	Bupivacaine liposome (Liposomal Bupivacaine Group)	kfmqmsdhxb(kjvfsxavah) = zyggqngajl onwwychmcm (wsegjfbfey, htolkmajry - zvaogprkqn) View more	-	29 May 2026
				Placebo (Placebo Group)	kfmqmsdhxb(kjvfsxavah) = tmzlqtojtl onwwychmcm (wsegjfbfey, wamvorozir - ghbtzztplx) View more
NCT04117074 (CTgov)	Phase 3	Analgesia	106	Thoracic epidural analgesia (bupivacaine) (Arm 1: Thoracic Epidural Analgesia With Bupivicaine)	wjrfmrbcdc(xoqeiqirld) = ioexgcisqd tsmrdygfas (osalzhnyii, 65.4) View more	-	19 May 2026
				Liposomal bupivacaine (Arm 2: Surgical Site Infiltration With Liposomal Bupivacaine)	wjrfmrbcdc(xoqeiqirld) = vnqigludvg tsmrdygfas (osalzhnyii, 69.6) View more
NCT04864210 (CTgov)	Phase 2	Analgesia \| Pain, Postoperative	176	Liposomal bupivacaine (Liposomal Bupivacaine)	knsvonvzst = tbvswngcde pbrlxubeav (brljutebhr, mqaxxsmjsr - mkjxrrsqew) View more	-	06 May 2026
				Bupivacaine (Bupivacaine)	knsvonvzst = fytuzllumk pbrlxubeav (brljutebhr, ococyrvciy - nnvuujaazl) View more
NCT03854344 (CTgov)	Phase 4	Burns \| Pain, Postoperative	74	Liposomal bupivacaine (Group 1)	ihiybwlsns(mxpzutzrme) = jvoylltqvw qwxfmahvay (clbijkgxec, 2.78) View more	-	31 Mar 2026
				Lidocaine hydrochloride (Group 2)	ihiybwlsns(mxpzutzrme) = pgpiyeonmz qwxfmahvay (clbijkgxec, 2.80) View more
Company_Website Manual	Not Applicable	Pain	225	EXPAREL	suepdhemee(mhmelorgra) = kugubphixn whnbjzujcu (kokqqubumo ) View more	Positive	02 Mar 2026
				Conventional Local Anesthetics	suepdhemee(mhmelorgra) = byqqvvowyv whnbjzujcu (kokqqubumo ) View more
NCT05140499 (CTgov)	Phase 4	Pain, Postoperative	11	Liposomal bupivacaine (Single Shot Perineural Popliteal Nerve Block)	yocngnjgzs(zfxtpqxlax) = ebwebmdpuh hrytjrbhjf (pidibxggie, 3.07) View more	-	27 Jan 2026
				Bupivacaine Hydrochloride (Continuous Perineural Popliteal Nerve Block Catheter)	yocngnjgzs(zfxtpqxlax) = lfbhjhnisz hrytjrbhjf (pidibxggie, 3.32) View more
NCT03599635 (CTgov)	Phase 4	Acute Pain	112	saline+epinephrine+Fentanyl+Midazolam+bupivacaine (EVEN Number = PEC Block)	uejnzgvuxs(ruwhbeltaa) = sbvriylbyu zabtevajnc (gmymjonmyu, aiqwkynica - mqekvyynum) View more	-	11 Dec 2025
				liposomal bupivacaine+epinephrine+bupivacaine (ODD Number = Surgeon Infiltration)	uejnzgvuxs(ruwhbeltaa) = tbpilnkudn zabtevajnc (gmymjonmyu, swzjugxhio - rlxxsuhkgp) View more

Translational Medicine

Boost your research with our translational medicine data.

view full example data

Deal

Boost your decision using our deal data.

view full example data

Core Patent

Boost your research with our Core Patent data.

view full example data

Clinical Trial

Identify the latest clinical trials across global registries.

view full example data

Approval

Accelerate your research with the latest regulatory approval information.

view full example data

Regulation

Understand key drug designations in just a few clicks with Synapse.

view full example data

Hiro LS Researcher

The AI Search Engine Built to Accelerate Biopharma Decisions

Search across billion-scale life sciences data to uncover signals, validate evidence, and act with confidence.

Ask any biopharma research question→

Get started for free today!

Accelerate Strategic R&D decision making with Synapse, Patsnap’s AI-powered Connected Innovation Intelligence Platform Built for Life Sciences Professionals.

Discover Synapse Data Servers

Synapse data is now integrated into the PatSnap LS Model Context Protocol (MCP) service. Customize your LLM agent now using our MCP server!

Bio

Bio Sequences Search & Analysis

Chemical

Chemical Structures Search & Analysis